Novo Nordisk A/S (NONOF) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 10.68 means the share price is 10.68 times one year of earnings per share; the S&P 500 usually sits near 20-25. Market cap $192B is the value of all shares combined. Beta 0.27: the stock has moved about 73% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerNovo Nordisk A/S (NONOF) trades at $43.19. Novo Nordisk A/S is a global healthcare company focused on diabetes and obesity care, as well as biopharmaceuticals. Market cap: $192B, Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for NONOF: NONOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NONOF against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
These figures come from statements filed 12 months ago — the most recent this company has published.
NONOF: 1/2 scored disciplines lean bullish. Dominant signal: Ray Dalio bullish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Novo Nordisk A/S (NONOF) Healthcare & Pipeline Overview
Novo Nordisk A/S, a leading healthcare company specializing in diabetes and obesity care, leverages its established global presence and innovative pharmaceutical products to maintain a strong market position within the biotechnology sector, underscored by a robust profit margin and significant dividend yield.
What Is the Investment Thesis for NONOF?
Novo Nordisk A/S presents a notable research candidate within the healthcare sector, driven by its strong market position in diabetes and obesity care. With a market capitalization of $192B and a profit margin of 33.1%, the company demonstrates financial stability and profitability. The dividend yield of 4.68% offers an attractive return for investors. Growth catalysts include the increasing global prevalence of diabetes and obesity, driving demand for Novo Nordisk's innovative treatments. Potential risks include regulatory challenges and competition from other pharmaceutical companies. The company's beta of 0.27 suggests relatively low volatility compared to the overall market.
Based on FMP financials and quantitative analysis
NONOF Key Highlights
Market capitalization of $192B, reflecting Novo Nordisk's significant presence in the healthcare sector.
- Profit margin of 33.1%, indicating strong profitability and efficient operations.
- Gross margin of 81.0%, showcasing the company's ability to maintain high pricing power and manage production costs effectively.
- Dividend yield of 4.68%, providing an attractive income stream for investors.
- Beta of 0.27, suggesting lower volatility compared to the overall market, making it a relatively stable investment.
Who Are NONOF's Competitors?
NONOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| AZNCF AstraZeneca PLC | $189.90 | -1.35% | $294B | — |
| CMXHF CSL Limited | $126.18 | 0.00% | $60.4B | — |
| ESLOF EssilorLuxottica S.A. | $171.57 | -4.45% | $78.9B | — |
| FSNUY Fresenius SE & Co. KGaA | $13.00 | +0.62% | $117B | — |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NONOF's Key Strengths?
Strong market position in diabetes and obesity care.
- Extensive portfolio of patented pharmaceutical products.
- Global distribution network.
- High profit margin.
What Are NONOF's Weaknesses?
Dependence on a limited number of key products.
- Exposure to patent expiration risks.
- Vulnerability to generic competition.
- Operational risks associated with manufacturing and supply chain.
What Could Drive NONOF Stock Higher?
Potential regulatory approvals for new diabetes and obesity treatments.
- Increasing global prevalence of diabetes and obesity driving demand for Novo Nordisk's products.
- Expansion into emerging markets with large patient populations.
- Strategic collaborations and acquisitions to expand product portfolio.
- Continued investment in research and development of innovative therapies.
What Are the Key Risks for NONOF?
Regulatory challenges and pricing pressures in key markets.
- Competition from other pharmaceutical companies developing similar treatments.
- Patent expiration risks and generic competition.
- Economic downturns and healthcare spending cuts impacting demand for products.
- Product liability claims and litigation.
What Are the Growth Opportunities for NONOF?
- Expansion in Emerging Markets: Novo Nordisk has a significant opportunity to expand its presence in emerging markets, where the prevalence of diabetes and obesity is rapidly increasing. These markets offer substantial growth potential due to their large populations and increasing healthcare spending. By tailoring its product offerings and distribution strategies to meet the specific needs of these markets, Novo Nordisk can capture a larger share of the global diabetes and obesity care market. Timeline: Ongoing.
- Development of Novel Therapies: Investing in the research and development of novel therapies for diabetes, obesity, and related chronic diseases represents a significant growth opportunity for Novo Nordisk. By developing innovative treatments with improved efficacy and safety profiles, the company can differentiate itself from competitors and capture a larger share of the market. This includes exploring new drug delivery systems and personalized medicine approaches. Market size: Multi-billion dollar potential. Timeline: Ongoing.
- Strategic Collaborations and Acquisitions: Novo Nordisk can pursue strategic collaborations and acquisitions to expand its product portfolio and geographic reach. Partnering with or acquiring companies with complementary technologies or market access can accelerate growth and enhance the company's competitive position. This includes exploring opportunities in areas such as digital health and telemedicine. Timeline: Ongoing.
- Focus on Preventative Care: Novo Nordisk can expand its focus on preventative care and early intervention strategies to address the root causes of diabetes and obesity. By developing and marketing products and services that promote healthy lifestyles and prevent the onset of these diseases, the company can tap into a growing market for preventative healthcare solutions. Timeline: Ongoing.
- Leveraging Digital Health Technologies: Integrating digital health technologies into its product offerings and services represents a significant growth opportunity for Novo Nordisk. This includes developing mobile apps, wearable devices, and telehealth platforms that enable patients to better manage their diabetes and obesity. By leveraging digital health technologies, Novo Nordisk can improve patient engagement, adherence, and outcomes. Timeline: Ongoing.
What Are NONOF's Competitive Advantages?
- Strong brand reputation and established market leadership in diabetes and obesity care.
- Extensive portfolio of patented pharmaceutical products.
- Global distribution network and established relationships with healthcare providers.
- Significant investment in research and development, leading to innovative therapies.
What Does NONOF Do?
Founded in 1923 and headquartered in Bagsvaerd, Denmark, Novo Nordisk A/S has evolved into a global healthcare company focused on diabetes and obesity care, as well as biopharmaceuticals. The company operates through two primary segments: Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment offers a range of products, including insulins, GLP-1 and related delivery systems, oral antidiabetic products, and treatments for obesity and other chronic diseases. The Biopharmaceuticals segment provides products in the areas of haemophilia, growth disorders, and hormone replacement therapy. Novo Nordisk's commitment to research and development is evident through its collaboration agreements with companies like Gilead Sciences, Inc. and Lumen Bioscience, Inc., aimed at exploring innovative strategies for delivering oral biologics for cardiometabolic diseases. With a workforce of over 77,000 employees, Novo Nordisk continues to expand its reach and impact in the global healthcare market, driven by its dedication to improving patient outcomes and addressing unmet medical needs.
What Products and Services Does NONOF Offer?
- Researches and develops pharmaceutical products.
- Manufactures pharmaceutical products.
- Markets pharmaceutical products globally.
- Offers treatments for diabetes and obesity.
- Provides products for haemophilia, growth disorders, and hormone replacement therapy.
- Collaborates with other companies to develop new therapies.
How Does NONOF Make Money?
- Develops and manufactures pharmaceutical products for diabetes, obesity, and other chronic diseases.
- Markets and sells these products through a global distribution network.
- Generates revenue through product sales and licensing agreements.
- Reinvests a portion of its revenue into research and development to innovate new therapies.
What Industry Does NONOF Operate In?
Novo Nordisk operates in the biotechnology industry, a segment of the healthcare sector characterized by rapid innovation and high growth potential. The increasing global prevalence of diabetes and obesity is driving demand for innovative treatments, benefiting companies like Novo Nordisk. The competitive landscape includes major pharmaceutical companies such as AZNCF (AstraZeneca), CMXHF (ChemoMetec A/S), and CSLLY (Sanofi), each vying for market share in the diabetes and obesity care market. The industry is subject to stringent regulatory requirements and faces ongoing pricing pressures.
Who Are NONOF's Key Customers?
- Patients with diabetes, obesity, haemophilia, growth disorders, and hormone deficiencies.
- Healthcare providers, including physicians, nurses, and hospitals.
- Pharmacies and distributors.
- Government healthcare systems and insurance companies.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scoring coverage unknown
- ● Price is current
- ● Latest filing 39 days ago
- ● No analyst coverage
- ● Reported in DKK, converted to USD
MoonshotScore History
Recorded daily since 2026-08-23 · 20 snapshots
| 2026-08-23 | 52 |
| 2026-08-27 | 52 |
| 2026-08-31 | 52 |
| 2026-09-04 | 52 |
| 2026-09-08 | 52 |
| 2026-09-11 | 52 |
What changed?
The score has stayed at 52.
Over the same 19 days the stock moved -7.7%.
Company Profile
Novo Nordisk A/S operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Bagsvaerd, Denmark.
Novo Nordisk A/S Financial Trajectory
Novo Nordisk A/S (NONOF) reported $12.18B in revenue for Q2 FY2026, a decline of 18.9% compared to the prior quarter. The company recorded net income of $3.26B, with diluted EPS of $0.73. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, NONOF averaged $1.02 in diluted EPS.
How Novo Nordisk A/S Is Valued
Novo Nordisk A/S carries a market capitalization of $192B, placing it in the large-cap category.
Key Financial Metrics
Return on equity for Novo Nordisk A/S stands at 59.1%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 19.6%, showing how much profit it generates from its asset base. NONOF trades at a trailing price-to-earnings ratio of 10.68, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 3.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.87 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 9.0%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Novo Nordisk A/S's Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.92 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Novo Nordisk A/S has beaten Wall Street's EPS estimate in 6 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 5.7% above estimates on average.
NONOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Strong market position in diabetes and obesity care.
- Extensive portfolio of patented pharmaceutical products.
- Global distribution network.
- High profit margin.
Bear Case
- Dependence on a limited number of key products.
- Exposure to patent expiration risks.
- Vulnerability to generic competition.
- Operational risks associated with manufacturing and supply chain.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 FY2026 | $12.18B | $3.26B | $0.73 |
| Q1 FY2026 | $15.02B | $7.54B | $1.69 |
| Q4 FY2025 | $12.25B | $4.16B | $0.94 |
| Q3 FY2025 | $11.63B | $3.10B | $0.70 |
Q2 FY2026 · filed 4 Aug 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis · Converted to USD from DKK at today's rate
NONOF Latest News
-
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo! Finance: NONOF News · Sep 10, 2026
-
Sector Update: Healthcare Stocks Decline Late Afternoon
Yahoo! Finance: NONOF News · Sep 4, 2026
-
Novo Nordisk (CPSE:NOVO B) Stock Fair Value Edges Higher As Analysts Rework Growth Assumptions
Yahoo! Finance: NONOF News · Jul 15, 2026
-
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
Yahoo! Finance: NONOF News · Jul 15, 2026
NONOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for NONOF.
Price Targets
Wall Street price target analysis for NONOF.
NONOF MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for NONOF; grades run from A+ (80-100) to F (below 30).
Latest News
AbbVie vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026?
Sector Update: Healthcare Stocks Decline Late Afternoon
Novo Nordisk (CPSE:NOVO B) Stock Fair Value Edges Higher As Analysts Rework Growth Assumptions
Vivani Medical Eyes August Human Trial for Semaglutide Implant After Novo Nordisk Deal
Leadership: Maziar Mike Doustdar
Unknown
Without specific details, it is impossible to provide a comprehensive bio, including career history, education, previous roles, or credentials.
Track Record: Information on Maziar Mike Doustdar's track record is not available in the provided context. Without specific details, it is impossible to assess key achievements, strategic decisions, or company milestones under their leadership.
NONOF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Novo Nordisk A/S (NONOF) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited information available to investors, and trading activity can be sporadic. Unlike companies listed on major exchanges like the NYSE or NASDAQ, OTC Other stocks often have less stringent listing standards and regulatory oversight, resulting in higher risks for investors.
- OTC Tier: OTC Other
- Limited information availability due to lower disclosure requirements.
- Potential for price manipulation and fraud.
- Higher bid-ask spreads and lower trading volumes.
- Increased volatility and price swings.
- Lack of regulatory oversight compared to major exchanges.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Check for any legal or regulatory issues.
- Evaluate the company's stock price history and trading volume.
- Consult with a financial advisor before investing.
- Understand the risks associated with OTC investments.
- Established history as Novo Nordisk A/S, founded in 1923.
- Global presence and operations in multiple countries.
- Significant market capitalization, despite being traded OTC.
- Presence in the healthcare sector with a focus on diabetes and obesity care.
- Collaboration agreements with reputable companies like Gilead Sciences, Inc.
Common Questions About NONOF (Healthcare)
Is NONOF a good stock?
Stock Expert AI does not rate NONOF buy, sell or hold. Novo Nordisk A/S has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What does Novo Nordisk A/S do?
Novo Nordisk A/S is a global healthcare company focused on developing and marketing pharmaceutical products for the treatment of diabetes, obesity, and other chronic diseases. The company operates through two segments: Diabetes and Obesity care, and Biopharm.
What are the key factors to evaluate for NONOF?
Evaluate NONOF on fundamentals, analyst consensus, and risk factors. P/E: 10.68x vs the S&P 500's ~20-25x. The dividend yield of 4.68% offers an attractive return for investors. Not financial advice.
How frequently does NONOF data refresh on this page?
NONOF's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 calculations are scheduled daily at 10:15 UTC; the score's own date shows its last successful run.
What has driven NONOF's recent stock price performance?
Novo Nordisk A/S (NONOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Strong market position in diabetes and obesity care. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NONOF overvalued or undervalued right now?
Novo Nordisk A/S (NONOF) trades at 10.68x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of NONOF?
Yes, most major brokerages offer fractional shares of Novo Nordisk A/S (NONOF) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track NONOF's earnings and financial reports?
Novo Nordisk A/S (NONOF) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for NONOF earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
No publishable V2 score is available for this stock yet.
Data provided for informational purposes only.
- Information is based on available data and may not be exhaustive.
- OTC market data may be limited and less reliable than exchange-listed data.